Exavir Therapeutics
Exavir Therapeutics is dedicated to transforming the standard of care in long-acting antivirals, focusing on innovative treatments for HIV and related conditions. They develop ultra-long-acting prodrugs and collaborate with partners like ViiV Healthcare to advance their pipeline of antiviral therapies.
Industries
Nr. of Employees
small (1-50)
Exavir Therapeutics
San Francisco, California, United States, North America
Products
Ultra-long-acting cabotegravir prodrug (partner-developed; Phase 1)
A prodrug formulation of an integrase inhibitor engineered for dosing intervals of approximately every six months or longer; clinical development is being conducted by a third-party pharmaceutical partner.
Long-acting dolutegravir prodrug (auto-injector–compatible)
A dolutegravir-based prodrug designed to maintain therapeutic concentrations for extended intervals (up to approximately four months) and formulated to be compatible with self-administration via an auto-injector device.
Ultra-long-acting tenofovir prodrug nanosuspension
A tenofovir prodrug formulated as a nanosuspension to provide sustained levels of the active metabolite (tenofovir-diphosphate) for treatment of HIV, hepatitis B, and HIV–HBV co-infection.
Ultra-long-acting cabotegravir prodrug (partner-developed; Phase 1)
A prodrug formulation of an integrase inhibitor engineered for dosing intervals of approximately every six months or longer; clinical development is being conducted by a third-party pharmaceutical partner.
Long-acting dolutegravir prodrug (auto-injector–compatible)
A dolutegravir-based prodrug designed to maintain therapeutic concentrations for extended intervals (up to approximately four months) and formulated to be compatible with self-administration via an auto-injector device.
Ultra-long-acting tenofovir prodrug nanosuspension
A tenofovir prodrug formulated as a nanosuspension to provide sustained levels of the active metabolite (tenofovir-diphosphate) for treatment of HIV, hepatitis B, and HIV–HBV co-infection.
Services
Licensing and collaboration for drug development
Out-licensing of long-acting antiviral candidates and collaboration with pharmaceutical partners that assume clinical development and commercialization responsibilities under milestone/royalty agreements.
Collaborative research funded by government awards
Execution of preclinical and early-stage program work supported by government grants and awards.
Licensing and collaboration for drug development
Out-licensing of long-acting antiviral candidates and collaboration with pharmaceutical partners that assume clinical development and commercialization responsibilities under milestone/royalty agreements.
Collaborative research funded by government awards
Execution of preclinical and early-stage program work supported by government grants and awards.
Expertise Areas
- Long-acting prodrug development
- Antiretroviral therapeutics (HIV, HBV, co-infection)
- Formulation development for extended-release injectables
- Preclinical PK/PD modeling and prediction
Key Technologies
- Prodrug chemistry for extended release
- Nanosuspension formulation
- Pharmacokinetic modeling
- Auto-injector–compatible formulation design